0-pi transitions in Josephson junctions with antiferromagnetic interlayers

We show that the dc Josephson current through superconductor-antiferromagnet-superconductor (S/AF/S) junctions manifests a remarkable atomic scale dependence on the interlayer thickness. At low temperatures the junction is either a 0- or pi-junction depending on whether the AF interlayer consists of an even or odd number of atomic layers. This is associated with different symmetries of the AF interlayers in the two cases. In the junction with odd AF interlayers an additional pi-0 transition can take place as a function of temperature. This originates from the interplay of spin-split Andreev bound states. Experimental implications of these theoretical findings are discussed.Comment: 4 pages, 2 figure

Low-energy quasiparticle states at superconductor-CDW interfaces

Quasiparticle bound states are found theoretically on transparent interfaces of d-wave superconductors (dSC) with charge density wave solids (CDW), as well as s-wave superconductors (sSC) with d-density waves (DDW). These bound states represent a combined effect of Andreev reflection from the superconducting side and an unconventional quasiparticle Q-reflection from the density wave solid. If the order parameter for a density wave state is much less than the Fermi energy, bound states with almost zero energy take place for an arbitrary orientation of symmetric interfaces. For larger values of the order parameter, dispersionless zero-energy states are found only on (110) interfaces. Two dispersive energy branches of subgap quasiparticle states are obtained for (100) symmetric interfaces. Andreev low-energy bound states, taking place in junctions with CDW or DDW interlayers, result in anomalous junction properties, in particular, the low-temperature behavior of the Josephson critical current.Comment: 6 pages, 2 figure

Синтез та вивчення протипухлинної активності похідних 1,4-діарил-5,6,7,8-тетрагідро-2,2а,8а-триазациклопента[cd]азуленів

Aim. To synthesize, prove the structural framework and study the antitumor activity of 1,4-diaryl-5,6,7,8-tetrahydro-2,2a,8a-triazacyclopenta [cd]azulene derivatives.Results and discussion. To determine the antineoplastic activity of 1-phenyl-4-aryl-5,6,7,8-tetrahydro-2,2a,8a-triazacyclopenta[cd]azulenes 7a-g and 1-(41-bromophenyl)-4-aryl-5,6,7,8-tetra-hydro-2,2a,8a-triazacyclopenta [cd]azulenes 7h-k the study in vitro was carried out on 60 lines of cancer cells (leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer and breast cancer) under the effect of the substance in the concentration of 10-5 mol/l according to the standard procedure of the mitotic activity assessment of the new potential bioactive compounds by the fluorescent coloring method (sulphorhodamine B as a dye) performed in the US National Institute of cancer within the Development Therapeutic Program.Experimental part. 2-Methoxy-3,4,5,6-tetrahydro-7H-azepine was obtained by alkylation of caprolactam with dimethyl sulfate. 3-Phenyl or (41-bromophenyl)-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine 4 a,b was obtained by condensation of 2-methoxy-3,4,5,6-tetrahydro-7H-azepine 1 with 4-bromobenzoic acid hydrazide and subsequent cyclization of the intermediate product. The 1Н-NMR spectra were recorded on a Bruker VXR-300 spectrometer (Germany) with the working frequency of 299.945 MHz, in DMSO-d6 using tetramethylsilane (TMS) as an internal standard. The purity of the compounds synthesized was controlled by TLC on the Silufol UV-254 plates in the system of chloroform – methanol (9 : 1). Conclusions. New chemical compounds – derivatives of 1-phenyl(41-bromphenyl)-4-aryl-5,6,7,8-tetrahydro-2,2a,8a-triaza-cyclopenta[cd]azulene have been synthesized. The anticancer activity of the compounds obtained on 60 lines of tumor cells in the US National Cancer Institute has been studied. The high-active compounds that exhibit high levels of the antitumor activity have been identified.Цель работы –синтезировать, доказать структурное строение и провести изучение противоопухолевой активности производных 1,4-диарил-5,6,7,8-тетрагидро-2,2А, 8а-триазациклопента[cd]азулена.Результаты и их обсуждение. Для определения противоопухолевой активности 1-фенил-4-арил-5,6,7,8-тетрагидро-2,2а, 8а-триазациклопента [cd] азулена 7a-g и 1-(41-бромфенил)-4-арил-5,6,7,8-тетрагидро-2,2а,8а-триазациклопента[cd]азулена 7h-k было проведено исследование in vitro на 60 линиях раковых клеток (лейкемии, легких, толстого кишечника, ЦНС, меланомы, яичников, почек, простаты, молочной железы) при воздействии вещества в концентрации 10-5 моль/л по стандартной процедуре оценки митотической активности новых потенциальных биологически активных соединений методом флуоресцентной окраски (краситель – сульфородамин Б), выполненных в Национальном институте рака США (National Cancer Institute of Health, USA) в рамках Development Therapeutic Program.Экспериментальная часть. 2-метокси-3,4,5,6-тетрагидро-7H-азепин получено алкилированием капролактама диметилсульфатом. 3-(41-бромфенил)-6,7,8,9-тетрагидро-5H-[1,2,4]триазоло[4,3-a]азепин получено конденсацией 2-метокси-3,4,5,6-тетрагидро-7H-азепин с гидразидом парабромбензойной кислоты и последующей циклизацией промежуточного продукта. Спектры ПМР были зарегистрированы на спектрометре Bruker VXR-300, рабочая частота – 299,945 МГц, внутренний стандарт ТМС. Контроль за чистотой синтезированных соединений осуществлялся с помощью ТСХ на пластинках Silufol UV-254 в системе хлороформ – метанол 9 : 1.Выводы. Синтезированы новые химические соединения – производные 1,4-диарил-5,6,7,8-тетрагидро-2,2а,8а-триазациклопента[cd]азулена. Изучена противораковая активность полученных соединений на 60 линиях опухолевых клеток в Национальном институте рака США. Идентифицированы высокоактивные соединения, которые проявили высокий уровень противоопухолевой активности.Мета роботи – синтезувати, довести структурну будову та провести вивчення протипухлинної активності похідних 1,4-діарил-5,6,7,8-тетрагідро-2,2а,8а-триазациклопента[cd]азуленів.Результати та їх обговорення. Для визначення протипухлинної активності 1-феніл-4-арил-5,6,7,8- тетрагідро-2,2а,8а-триазациклопента[cd]азулену 7a-g та 1-(41-бромфеніл)-4-арил-5,6,7,8-тетрагідро-2,2а,8а-триазациклопента[cd]азулену 7h-k дослідження проведено in vitro на 60 лініях ракових клітин (лейкемії, легень, товстого кишківника, ЦНС, меланоми, яєчників, нирок, простати, молочної залози) при дії речовини в концентрації 10-5 моль/л за стандартною процедурою оцінки мітотичної активності нових потенційних біологічно активних сполук методом флуоресцентного зафарбування (барвник – сульфородамін Б), виконаних у Національному інституті раку США (National Cancer Institute of Health, USA) в рамках Development Therapeutic Program.Експериментальна частина. 2-Метокси-3,4,5,6-тетрагідро-7H-азепін одержано алкілуванням капролактаму диметилсульфатом. 3-(41-Бромфеніл)-6,7,8,9-тетрагідро-5H-[1,2,4]триазоло[4,3-a]азепін одержано конденсацією 2-метокси-3,4,5,6-тетрагідро-7H-азепіну з гідразидом пара-бромбензойної кислоти та подальшою циклізацією проміжного продукту. Спектри ПМР були зареєстровані на спектрометрі Bruker VXR-300, робоча частота – 299,945 МГц, внутрішній стандарт ТМС. Контроль за чистотою синтезованих сполук здійснювався за допомогою ТШХ на пластинках Silufol UV-254 в системі хлороформ – метанол 9 : 1.Висновки. Синтезовані нові хімічні речовини – похідні 1,4-діарил-5,6,7,8-тетрагідро-2,2а,8а-триазациклопента [cd]азулену. Вивчена протиракова активність одержаних сполук на 60 лініях пухлинних клітин в Національному інституті раку США. Ідентифіковані високоактивні сполуки, які проявили високий рівень протипухлинної активності

Proximity-driven source of highly spin-polarized ac current on the basis of superconductor/weak ferromagnet/superconductor voltage-biased Josephson junction

We theoretically investigate an opportunity to implement a source of highly spin-polarized ac current on the basis of superconductor/weak ferromagnet/superconductor (SFS) voltage-biased junction in the regime of essential proximity effect and calculate the current flowing through the probe electrode tunnel coupled to the ferromagnetic interlayer region. It is shown that while the polarization of the dc current component is generally small in case of weak exchange field of the ferromagnet, there is an ac component of the current in the system. This ac current is highly spin-polarized and entirely originated from the non-equilibrium proximity effect in the interlayer. The frequency of the current is controlled by the voltage applied to SFS junction. We discuss a possibility to obtain a source of coherent ac currents with a certain phase shift between them by tunnel coupling two probe electrodes at different locations of the interlayer region.Comment: 8 pages, 5 figure

Synthesis and anticancer properties of 1-(2-isopropyl-5-methylphenoxymethyl)-3R-4-aryl-5,6,7,8-tetrahydro-2,2а,8а-triazacyclopenta[cd]azulene derivatives

In recent years, attention to itself is attracted to the problem of treatment of cancer that is caused by increase in patients, especially of working age. Therefore, the enlargement of the arsenal of anticancer medicines of a wide spectrum of action is actual. The purpose of the study was to synthesize substances with potentially antitumor properties in a series 1-(2-isopropyl-5-methylphenoxymethyl)-3R-4-aryl-5,6,7,8-tetrahydro-2,2а,8а-triazacyclopenta[cd]azulene derivatives and to study the effect of synthesized compounds on inhibition of growth (or their destruction) of a wide range of cancer. The objects of the study were derivatives of 1-(2-isopropyl-5-methylphenoxymethyl)-3R-4-aryl-5,6,7,8-tetrahydro-2,2а,8а-triazacyclopenta[cd]azulene, which were synthesized by refluxing 3-(2-isopropyl-5-methylphenoxymethyl)-6,7,8,9-tetrahydro-5Н-[1,2,4]triazolo[4,3-a]azepine with с appropriate α-halogenketones in ethyl acetate and further cyclization in an alkaline medium. Использовали данные NMR 1Н spectroscopy data were used. The primary evaluation of anticancer activity was carried out National Cancer Institute of Health, USA within the Development Therapeutic Program. A series of new of 1-(2-isopropyl-5-methylphenoxymethyl)-3R-4-aryl-5,6,7,8-tetrahydro-2,2а,8а-triazacyclopenta[cd]azulene derivatives was synthesized, their structure and purity were confirmed by NMR 1Н spectroscopy. The anticancer activity of the synthesized compounds was studied both at a concentration of 10-5 mol/l and in a concentration gradient of 10-4‒10-8 mol/l in experiments in vivo on cancer cell lines. It is shown that insertion of methyl group into position 3 of heterocyclic system of the basic structure of 4-aryl-5,6,7,8-tetrahydro-2,2a,8a-triazacyclopenta[cd]azulene leads to an increase in the anticancer effect. It is found that the tested compounds showed high anticancer effect on all types of cancer cell lines investigated – leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer and breast cancer

Synthesis and anаlgеsic properties of (3-allyl-4-aryl-3H-thiazol-2-ylidene)-[4-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)phenyl]amine derivatives

In recent years, attention to itself attracted by the problem of pain treatment, which is due to a noticeable increase in patients, especially the able-bodied age. The aim of the study was to synthesize substances with potentially analgesic properties in the series of hydrobromides (3-allyl-4-aryl-3H-thiazol-2-ylidene)-[4-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)phenyl]amine and to study the effect of the synthesized compounds on the analgesic activity. The objects of the study were (3-allyl-4-aryl-3H-thiazol-2-ylidene)-[4-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)phenyl]amine derivatives, which were synthesized by boiling a thiourea with the corresponding α-haloketones in ethanol medium. Data of NMR 1H spectroscopy were used. The primary evaluation of analgesic activity was carried out on models of thermal («Hot plate») and chemical («Acetic acid cramps») stimulation. A new series of (3-allyl-4-aryl-3H-thiazol-2-ylidene)-[4-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)phenyl]amine derivatives were synthesized and their structure and purity were confirmed by NMR 1H spectroscopy. The analgesic activity of hydrobromide 3-allyl-4-phenyl-3H-thiazol-2-ylidene)-[4-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)phenyl]amine were studied to identify the «structure‒activity» relationship taking into account earlier studies. Screening for analgesic activity for the hydrobromide 3-allyl-4-phenyl-3H-thiazol-2-ylidene)-[4-(6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepin-3-yl)phenyl]-amine were shown that the replacement of the ethyl radical by allyl in the third position of the thiazole ring leads to a decrease in analgesic activity. Moreover, the compound possesses a moderate analgesic effect compared to the reference drug ketorolac

Анальгезивна та протизапальна дії похідних 5,7-діацил- 3-H(алкіл)-6-арил-5Н-[1,2,4]тріазоло[3,4-b][1,3,4]тіадіазину

The search for new analgesic and anti-inflammatory drugs, exceeding by efficacy and/or safety the existinganalogues is very important and relevant. The nitrogenous heterocycles are promising in this respect, in particular,the compounds containing an imidazole triazol and tіadiazin moiety. The aim of the current study was to investigatethe antiexudative and antinociceptive activity of new derivatives of 5,7-diacyl-3-H(alkyl)-6-aryl-5H[1,2,4]triazol[3,4-b][1,3,4]thiadiazine.The antinociceptive and antiexudative activity studies were carried out on the white nonlinear mice. Theexperimental evaluation of specific activity was carried out on the models “Hot plate”, acetic acid induced writhing(antinociceptive action) and carrageenan edema (antiexudative action). The substance was used in a single oral routadministration in a dose of 25 mg/kg. Ketorolac was used as a reference product in the dose of 25 mg/kg (models“Hot plate”, acetic acid induced writhing). Diclofenac was used as a reference product in the dose of 25 mg/kg onthe model carrageenan edema. The experimental study showed the antinociceptive and antiexudative effects of thederivatives. The antinociceptive activity of 5,7-diacyl-3-H(alkіl)-6-aryl-5H[1,2,4]triazol[3,4-b][1,3,4]tіadiazin derivatiesrelated to the modification structure in the para position of benzene ring. The antiexudative activity is associated withacetyl groups thiadiazine ring. The most promising compound IFT_247 showed a significant antinociceptive effect,which is comparable to an active comparator ketorolac: “Hot plate” +232.46 % and +112.71 %; acetic acid inducedwrithing -66.67 % and -61.02 %, respectively.Поиск новых анальгезирующих и противовоспалительных препаратов, превосходящих по эффектив-ности и/или безопасности существующие аналоги, важен и актуален. В этом отношении перспективныазотистые гетероциклы, в частности соединения, содержащие в себе триазоловый и тиадиазиновыйфрагменты.Была поставлена цель исследовать антиноцицептивную и антиэксудативную активность новыхпроизводных 5,7-диацил-3-H(алкил)-6-арил-5Н-[1,2,4]триазоло[3,4-b][1,3,4]тиадиазина.Исследование проведено на белых нелинейных мышах обоего пола. Оценено антиноцицептивную иантиэксудативную активность пяти производных 5,7-диацил-3-H(алкил)-6-арил-5Н-[1,2,4]триазоло[3,4-b][1,3,4]тиадиазина на моделях “горячей пластины, уксуснокислых “корчей” (антиноцицептивный эффект)и каррагенинового отека (антиэкссудативное действие) при однократном внутрижелудочном введении вдозе 25 мг/кг. В качестве препаратов сравнения использовали кеторолак в дозе 25 мг/кг (“горячая пласти-на”, уксуснокислые “корчи”) и диклофенак натрия в дозе 25 мг/кг (каррагениновый отек). Исследованныесоединения показали наличие достоверного антиноцицептивного и антиэкссудативного эффектов.Антиноцицептивная активность ряда связана с модификацией структуры 5,7-диацил-3-H(алкил)-6-арил-5Н-[1,2,4]триазоло[3,4-b][1,3,4]тиадиазина в параположении бензольного кольца. Антиэкссудативнаяактивность – с ацетиловыми группами тиадиазинового кольца. Наиболее перспективным являетсясоединение IFT_247, проявляющее значительный анальгезирующий эффект в эксперименте и не усту-пающее по активности препарату сравнения – кеторолаку: “горячая пластина” – +232,46 и +112,71 %;уксуснокислые “корчи” – -66,67 и -61,02 % соответственно.Пошук нових анальгезивних і протизапальних препаратів, що переважають за ефективністю та/абобезпекою існуючі аналоги, є важливим і актуальним. У цьому відношенні перспективні азотисті гетеро-цикли, зокрема сполуки, що містять у собі тріазоловий і тіадіазиновий фрагменти.Було поставлено мету дослідити антиноцицептивну та антиексудативну активність нових похідних5,7-діацил-3-H(алкіл)-6-арил-5Н-[1,2,4]тріазоло[3,4-b][1,3,4]тіадіазину.Дослідження проведено на білих нелінійних мишах обох статей. Оцінено антиноцицептивну йантиексудативну активність п’яти похідних 5,7-діацил-3-H(алкіл)-6-арил-5Н-[1,2,4]тріазоло[3,4-b][1,3,4]тіадіазину на моделях “гарячої пластини”, оцтовокислих “корчів” (антиноцицептивний ефект) ікарагенінового набряку (антиексудативна дія) при одноразовому внутрішньошлунковому введенні в дозі25 мг/кг. Як препарати порівняння використовували кеторолак у дозі 25 мг/кг (“гаряча пластина”, оцтовокислі“корчі”) і диклофенак натрію в дозі 25 мг/кг (карагеніновий набряк). Досліджені сполуки показали наявністьдостовірного антиноцицептивного й антиексудативного ефектів. Антиноцицептивна активністьряду пов’язана з модифікацією структури 5,7-діацил-3-H(алкіл)-6-арил-5Н-[1,2,4]тріазоло[3,4-b][1,3,4]тіадіазину в параположенні бензольного кільця. Антиексудативна активність – з ацетиловими групамитіадіазинового кільця. Найбільш перспективною є сполука IFT_247, що проявляє значний анальгезивнийефект в експерименті й не поступається за активністю препарату порівняння – кеторолаку: “гарячапластина” – +232,46 і +112,71 %; оцтовокислі “корчі” – -66,67 і -61,02 % відповідно

ФЛУОРЕСЦЕНТНАЯ ДИАГНОСТИКА КАРИЕСА ЗУБОВ

The results obtained in studies of laser-induced fluorescence of the normal and carries-affected dental tissues are presented. The possibility of detection of considerable depth caries with use of the specially designed spectrometric system with excitation by a semiconductor laser source with a wavelength of 684 nm for fluorescence is shown.Приведены результаты исследований лазерно-возбуждаемой флуоресценции тканей зубов в норме и пораженных кариесом. Показано, что при использовании для возбуждения флуоресценции разработанного спектрометрического комплекса с возбуждением полупроводниковым лазерным источником с длиной волны 684 нм возможно детектирование глубоко расположенного кариеса

Mutation of RNA Pol III Subunit rpc2/polr3b Leads to Deficiency of Subunit Rpc11 and Disrupts Zebrafish Digestive Development

The role of RNA polymerase III (Pol III) in developing vertebrates has not been examined. Here, we identify a causative mutation of the second largest Pol III subunit, polr3b, that disrupts digestive organ development in zebrafish slim jim (slj) mutants. The slj mutation is a splice-site substitution that causes deletion of a conserved tract of 41 amino acids in the Polr3b protein. Structural considerations predict that the slj Pol3rb deletion might impair its interaction with Polr3k, the ortholog of an essential yeast Pol III subunit, Rpc11, which promotes RNA cleavage and Pol III recycling. We engineered Schizosaccharomyces pombe to carry an Rpc2 deletion comparable to the slj mutation and found that the Pol III recovered from this rpc2-Δ yeast had markedly reduced levels of Rpc11p. Remarkably, overexpression of cDNA encoding the zebrafish rpc11 ortholog, polr3k, rescued the exocrine defects in slj mutants, indicating that the slj phenotype is due to deficiency of Rpc11. These data show that functional interactions between Pol III subunits have been conserved during eukaryotic evolution and support the utility of zebrafish as a model vertebrate for analysis of Pol III function

Immunoglobulin, glucocorticoid, or combination therapy for multisystem inflammatory syndrome in children: a propensity-weighted cohort study

Background: Multisystem inflammatory syndrome in children (MIS-C), a hyperinflammatory condition associated with SARS-CoV-2 infection, has emerged as a serious illness in children worldwide. Immunoglobulin or glucocorticoids, or both, are currently recommended treatments. Methods: The Best Available Treatment Study evaluated immunomodulatory treatments for MIS-C in an international observational cohort. Analysis of the first 614 patients was previously reported. In this propensity-weighted cohort study, clinical and outcome data from children with suspected or proven MIS-C were collected onto a web-based Research Electronic Data Capture database. After excluding neonates and incomplete or duplicate records, inverse probability weighting was used to compare primary treatments with intravenous immunoglobulin, intravenous immunoglobulin plus glucocorticoids, or glucocorticoids alone, using intravenous immunoglobulin as the reference treatment. Primary outcomes were a composite of inotropic or ventilator support from the second day after treatment initiation, or death, and time to improvement on an ordinal clinical severity scale. Secondary outcomes included treatment escalation, clinical deterioration, fever, and coronary artery aneurysm occurrence and resolution. This study is registered with the ISRCTN registry, ISRCTN69546370. Findings: We enrolled 2101 children (aged 0 months to 19 years) with clinically diagnosed MIS-C from 39 countries between June 14, 2020, and April 25, 2022, and, following exclusions, 2009 patients were included for analysis (median age 8·0 years [IQR 4·2–11·4], 1191 [59·3%] male and 818 [40·7%] female, and 825 [41·1%] White). 680 (33·8%) patients received primary treatment with intravenous immunoglobulin, 698 (34·7%) with intravenous immunoglobulin plus glucocorticoids, 487 (24·2%) with glucocorticoids alone; 59 (2·9%) patients received other combinations, including biologicals, and 85 (4·2%) patients received no immunomodulators. There were no significant differences between treatments for primary outcomes for the 1586 patients with complete baseline and outcome data that were considered for primary analysis. Adjusted odds ratios for ventilation, inotropic support, or death were 1·09 (95% CI 0·75–1·58; corrected p value=1·00) for intravenous immunoglobulin plus glucocorticoids and 0·93 (0·58–1·47; corrected p value=1·00) for glucocorticoids alone, versus intravenous immunoglobulin alone. Adjusted average hazard ratios for time to improvement were 1·04 (95% CI 0·91–1·20; corrected p value=1·00) for intravenous immunoglobulin plus glucocorticoids, and 0·84 (0·70–1·00; corrected p value=0·22) for glucocorticoids alone, versus intravenous immunoglobulin alone. Treatment escalation was less frequent for intravenous immunoglobulin plus glucocorticoids (OR 0·15 [95% CI 0·11–0·20]; p<0·0001) and glucocorticoids alone (0·68 [0·50–0·93]; p=0·014) versus intravenous immunoglobulin alone. Persistent fever (from day 2 onward) was less common with intravenous immunoglobulin plus glucocorticoids compared with either intravenous immunoglobulin alone (OR 0·50 [95% CI 0·38–0·67]; p<0·0001) or glucocorticoids alone (0·63 [0·45–0·88]; p=0·0058). Coronary artery aneurysm occurrence and resolution did not differ significantly between treatment groups. Interpretation: Recovery rates, including occurrence and resolution of coronary artery aneurysms, were similar for primary treatment with intravenous immunoglobulin when compared to glucocorticoids or intravenous immunoglobulin plus glucocorticoids. Initial treatment with glucocorticoids appears to be a safe alternative to immunoglobulin or combined therapy, and might be advantageous in view of the cost and limited availability of intravenous immunoglobulin in many countries. Funding: Imperial College London, the European Union's Horizon 2020, Wellcome Trust, the Medical Research Foundation, UK National Institute for Health and Care Research, and National Institutes of Health